[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pd1\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pd1":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":5},"100427192","phase-1-engineered-tilscar-tils-to-treat-advanced-solid-tumors-100427192",false,"NCT04842812","Engineered TILs\u002FCAR-TILs to Treat Advanced Solid Tumors","Engineered TILs\u002FCAR-TILs With PD1 Knockout and Anti-PD1\u002FCTLA4-scFv Secreting or CARs Against Various Antigens to Treat Advanced Solid Tumors","Inclusion Criteria:\n\n1. Patients with advanced cancers that failed to current available therapies;\n2. Life expectancy \\>12 weeks;\n3. Adequate heart, lung, liver, kidney functions;\n4. Available for tumor biopsy or cancerous effusions;\n5. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n\nExclusion Criteria:\n\n1. Had accepted gene therapy before;\n2. Severe virus infection such as HBV, HCV, HIV, et al; Known HIV positivity;\n3. Active infectious disease related to bacteria, virus, fungi, et al;\n4. Other severe diseases that the investigators consider not appropriate;\n5. Pregnant or lactating women;\n6. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent\u002Fkg\u002Fday);\n7. Other conditions that the investigators consider not appropriate.","ALL","18 Years","85 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.",[27,28,29,30,31,32,33,34],"Liver Cancer","Lung Cancer","Breast Cancer","Colo-rectal Cancer","Brain Tumor","Solid Tumor, Adult","PD1","CTLA4",[36,28,37,38,39,33,34,40,41,42,43],"liver Cancer","Solid Tumor","TIL","CAR-TIL","GPC3","Mesothelin","B7-H3","CRISPRA-CAS9","RECRUITING","2024-06-22",{"date":47,"type":48},"2024-06-25","ACTUAL",{"date":50,"type":48},"2021-01-01",{"date":52,"type":21},"2035-01-01",{"name":54,"class":55},"Second Affiliated Hospital of Guangzhou Medical University","OTHER"]